{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:07:35Z","timestamp":1789427255225,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02848-5","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:01:50Z","timestamp":1789426910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-1 receptor-associated kinase 1 controls chemoresistance and immuno-killing in non-small cell lung cancer"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1815-3285","authenticated-orcid":false,"given":"Sabrina","family":"Digiovanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Giannotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Alessandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Meoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Doronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parab","family":"Sushant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Balmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9350-9652","authenticated-orcid":false,"given":"Muhlis","family":"Akman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kopecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Arigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Wens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Tarallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-9087","authenticated-orcid":false,"given":"Alessandro","family":"Bertero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rolando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisella","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0021-1428","authenticated-orcid":false,"given":"Massimo","family":"Massaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Calogero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-1341","authenticated-orcid":false,"given":"Federico","family":"Bussolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Vittorio","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6043-3794","authenticated-orcid":false,"given":"Iris Chiara","family":"Salaroglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Riganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"2848_CR1","doi-asserted-by":"publisher","first-page":"13323","DOI":"10.1038\/s41598-021-92725-8","volume":"11","author":"JW Chen","year":"2021","unstructured":"Chen, J. W. & Dhahbi, J. Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods. Sci. Rep. 11, 13323\u201313323 (2021).","journal-title":"Sci. Rep."},{"key":"2848_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S2213-2600(24)00428-4","volume":"13","author":"G Luo","year":"2025","unstructured":"Luo, G. et al. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir. Med. 13, 348\u2013363 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2848_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s12272-021-01312-y","volume":"44","author":"H-Y Min","year":"2021","unstructured":"Min, H.-Y. & Lee, H.-Y. Mechanisms of resistance to chemotherapy in non-small cell lung cancer. Arch. Pharm. Res. 44, 146\u2013164 (2021).","journal-title":"Arch. Pharm. Res."},{"key":"2848_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/BF02215949","volume":"69","author":"T Licht","year":"1994","unstructured":"Licht, T., Pastan, I., Gottesman, M. & Herrmann, F. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann. Hematol. 69, 159\u2013171 (1994).","journal-title":"Ann. Hematol."},{"key":"2848_CR5","doi-asserted-by":"publisher","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","volume":"22","author":"SV Ambudkar","year":"2003","unstructured":"Ambudkar, S. V., Kimchi-Sarfaty, C., Sauna, Z. E. & Gottesman, M. M. P-glycoprotein: from genomics to mechanism. Oncogene 22, 7468\u20137485 (2003).","journal-title":"Oncogene"},{"key":"2848_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0005-2736(99)00150-9","volume":"1461","author":"Q Mao","year":"1999","unstructured":"Mao, Q., Leslie, E. M., Deeley, R. G. & Cole, S. P. C. ATPase activity of purified and reconstituted multidrug resistance protein MRP1 from drug-selected H69AR cells. Biochim. Biophys. Acta 1461, 69\u201382 (1999).","journal-title":"Biochim. Biophys. Acta"},{"key":"2848_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0005-2736(99)00168-6","volume":"1461","author":"DR Hipfner","year":"1999","unstructured":"Hipfner, D. R., Deeley, R. G. & Cole, S. P. C. Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461, 359\u2013376 (1999).","journal-title":"Biochim. Biophys. Acta"},{"key":"2848_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP\u2013dependent transporters. Nat. Rev. Cancer 2, 48\u201358 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"2848_CR9","doi-asserted-by":"crossref","unstructured":"Chen, S. et al. Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments. Front. Immunol. 14, 1094764 (2023).","DOI":"10.3389\/fimmu.2023.1094764"},{"key":"2848_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1006\/geno.1994.1237","volume":"21","author":"MF Luciani","year":"1994","unstructured":"Luciani, M. F., Denizot, F., Savary, S., Mattei, M. G. & Chimini, G. Cloning of two novel ABC transporters mapping on human chromosome 9. Genomics 21, 150\u2013159 (1994).","journal-title":"Genomics"},{"key":"2848_CR11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/11905","volume":"22","author":"A Brooks-Wilson","year":"1999","unstructured":"Brooks-Wilson, A. et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22, 336\u2013345 (1999).","journal-title":"Nat. Genet."},{"key":"2848_CR12","doi-asserted-by":"publisher","first-page":"15663","DOI":"10.1038\/ncomms15663","volume":"8","author":"B Castella","year":"2017","unstructured":"Castella, B. et al. The ATP-binding cassette transporter A1 regulates phosphoantigen release and V\u03b39V\u03b42 T cell activation by dendritic cells. Nat. Commun. 8, 15663\u201315663 (2017).","journal-title":"Nat. Commun."},{"key":"2848_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13046-022-02447-6","volume":"41","author":"IC Salaroglio","year":"2022","unstructured":"Salaroglio, I. C. et al. Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer. J. Exp. Clin. Cancer Res. 41, 243\u2013243 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2848_CR14","doi-asserted-by":"publisher","first-page":"103537","DOI":"10.1016\/j.drudis.2023.103537","volume":"28","author":"MS Pote","year":"2023","unstructured":"Pote, M. S. & Gacche, R. N. ATP-binding cassette efflux transporters and MDR in cancer. Drug Discov. Today 28, 103537\u2013103537 (2023).","journal-title":"Drug Discov. Today"},{"key":"2848_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2174\/138920111795164075","volume":"12","author":"EI Stolarczyk","year":"2011","unstructured":"Stolarczyk, E. I., Reiling, C. J. & Paumi, C. M. Regulation of ABC transporter function via phosphorylation by protein kinases. Curr. Pharm. Biotechnol. 12, 621\u2013635 (2011).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"2848_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1042\/BST20150128_2","volume":"44","author":"B Aryal","year":"2016","unstructured":"Aryal, B., Laurent, C. & Geisler, M. Correction: Learning from each other: ABC transporter regulation by protein phosphorylation in plant and mammalian systems. Biochem. Soc. Trans. 44, 663\u2013673 (2016).","journal-title":"Biochem. Soc. Trans."},{"key":"2848_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1124\/dmd.118.080663","volume":"46","author":"RR Crawford","year":"2018","unstructured":"Crawford, R. R., Potukuchi, P. K., Schuetz, E. G. & Schuetz, J. D. Beyond competitive inhibition: regulation of ABC transporters by kinases and protein-protein interactions as potential mechanisms of drug-drug interactions. Drug Metab. Dispos. 46, 567\u2013580 (2018).","journal-title":"Drug Metab. Dispos."},{"key":"2848_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar, K. S. et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol. Cancer 17, 48\u201348 (2018).","journal-title":"Mol. Cancer"},{"key":"2848_CR19","doi-asserted-by":"publisher","first-page":"1133354","DOI":"10.3389\/fimmu.2023.1133354","volume":"14","author":"M Pereira","year":"2023","unstructured":"Pereira, M. & Gazzinelli, R. T. Regulation of innate immune signaling by IRAK proteins. Front. Immunol. 14, 1133354\u20131133354 (2023).","journal-title":"Front. Immunol."},{"key":"2848_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/bjc.2014.513","volume":"112","author":"GW Rhyasen","year":"2015","unstructured":"Rhyasen, G. W. & Starczynowski, D. T. IRAK signalling in cancer. Br. J. Cancer 112, 232\u2013237 (2015).","journal-title":"Br. J. Cancer"},{"key":"2848_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/MOH.0000000000000693","volume":"29","author":"J Bennett","year":"2022","unstructured":"Bennett, J. & Starczynowski, D. T. IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. 29, 8\u201319 (2022).","journal-title":"Curr. Opin. Hematol."},{"key":"2848_CR22","doi-asserted-by":"publisher","first-page":"8746","DOI":"10.1038\/ncomms9746","volume":"6","author":"ZN Wee","year":"2015","unstructured":"Wee, Z. N. et al. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat. Commun. 6, 8746\u20138746 (2015).","journal-title":"Nat. Commun."},{"key":"2848_CR23","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-20-2125","volume":"81","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Targeting the IRAK1\u2013S100A9 axis overcomes resistance to paclitaxel in nasopharyngeal carcinoma. Cancer Res. 81, 1413\u20131425 (2021).","journal-title":"Cancer Res."},{"key":"2848_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey, R. W. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 18, 452\u2013464 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2848_CR25","doi-asserted-by":"publisher","first-page":"7759","DOI":"10.1038\/s41598-023-33954-x","volume":"13","author":"L Manganaro","year":"2023","unstructured":"Manganaro, L. et al. Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer. Sci. Rep. 13, 7759\u20137759 (2023).","journal-title":"Sci. Rep."},{"key":"2848_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bph.16257","volume":"181","author":"B Gy\u0151rffy","year":"2024","unstructured":"Gy\u0151rffy, B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br. J. Pharmacol. 181, 362\u2013374 (2024).","journal-title":"Br. J. Pharmacol."},{"key":"2848_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13046-024-03142-4","volume":"43","author":"M Akman","year":"2024","unstructured":"Akman, M. et al. TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer. J. Exp. Clin. Cancer Res. 43, 219\u2013219 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2848_CR28","doi-asserted-by":"crossref","unstructured":"Zheng, Y. & He, J.-Q. Interleukin receptor associated kinase 1 signaling and its association with cardiovascular diseases. Rev. Cardiovasc. Med. 23, 97 (2022).","DOI":"10.31083\/j.rcm2303097"},{"key":"2848_CR29","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938\u2013945 (2015).","journal-title":"Nat. Med."},{"key":"2848_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-019-0518-z","volume":"7","author":"A Capasso","year":"2019","unstructured":"Capasso, A. et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J. Immunother. Cancer 7, 37\u201337 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2848_CR31","doi-asserted-by":"publisher","first-page":"13507","DOI":"10.1073\/pnas.1714386114","volume":"114","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. Crystal structure of human IRAK1. Proc. Natl. Acad. Sci. USA. 114, 13507\u201313512 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2848_CR32","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1021\/acs.jmedchem.5b01267","volume":"59","author":"M H\u00fcgle","year":"2016","unstructured":"H\u00fcgle, M. et al. 4-Acyl pyrrole derivatives yield novel vectors for designing inhibitors of the acetyl-lysine recognition site of BRD4(1). J. Med. Chem. 59, 1518\u20131530 (2016).","journal-title":"J. Med. Chem."},{"key":"2848_CR33","doi-asserted-by":"crossref","unstructured":"Liu, M. et al. A pan-cancer analysis of irak1 expression and their association with immunotherapy response. Front. Mol. Biosci. 9, 904959 (2022).","DOI":"10.3389\/fmolb.2022.904959"},{"key":"2848_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.33263\/BRIAC136.593","volume":"13","author":"HF Samaneh Rahemi","year":"2023","unstructured":"Samaneh Rahemi, H. F. Inhibition of IRAK signaling can improve topotecan sensitivity of breast cancer cell lines by decrease of P-gp gene expression. Biointerface Res. Appl. Chem. 13, 593\u2013593 (2023).","journal-title":"Biointerface Res. Appl. Chem."},{"key":"2848_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41419-024-06717-3","volume":"15","author":"D Standing","year":"2024","unstructured":"Standing, D. et al. Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer. Cell Death Dis. 15, 362\u2013362 (2024).","journal-title":"Cell Death Dis."},{"key":"2848_CR36","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1158\/0008-5472.CAN-17-2445","volume":"78","author":"BY Cheng","year":"2018","unstructured":"Cheng, B. Y. et al. IRAK1 augments cancer stemness and drug resistance via the AP-1\/AKR1B10 signaling cascade in hepatocellular carcinoma. Cancer Res. 78, 2332\u20132342 (2018).","journal-title":"Cancer Res."},{"key":"2848_CR37","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1159\/000491528","volume":"47","author":"K Ren","year":"2018","unstructured":"Ren, K., Jiang, T., Zhou, H.-F., Liang, Y. & Zhao, G.-J. Apigenin retards atherogenesis by promoting ABCA1-mediated cholesterol efflux and suppressing inflammation. Cell. Physiol. Biochem. 47, 2170\u20132184 (2018).","journal-title":"Cell. Physiol. Biochem."},{"key":"2848_CR38","doi-asserted-by":"publisher","first-page":"e1949","DOI":"10.1038\/cddis.2015.212","volume":"6","author":"L Guo","year":"2015","unstructured":"Guo, L. et al. IRAK1 mediates TLR4-induced ABCA1 downregulation and lipid accumulation in VSMCs. Cell Death Dis. 6, e1949\u2013e1949 (2015).","journal-title":"Cell Death Dis."},{"key":"2848_CR39","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.2015.63.0970","volume":"34","author":"E Brambilla","year":"2016","unstructured":"Brambilla, E. et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J. Clin. Oncol. 34, 1223\u20131230 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2848_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/14728222.2022.2117610","volume":"26","author":"SR Savla","year":"2022","unstructured":"Savla, S. R., Prabhavalkar, K. S. & Bhatt, L. K. Liver X receptor: a potential target in the treatment of atherosclerosis. Expert Opin. Ther. Targets 26, 645\u2013658 (2022).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2848_CR41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s43018-022-00376-z","volume":"3","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. A local human V\u03b41 T cell population is associated with survival in nonsmall-cell lung cancer. Nat. Cancer 3, 696\u2013709 (2022).","journal-title":"Nat. Cancer"},{"key":"2848_CR42","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.7150\/jca.105586","volume":"16","author":"Z Chen","year":"2025","unstructured":"Chen, Z. et al. Integrating of radiomics and single-cell transcriptomics uncovers the crucial role of \u03b3\u03b4 T cells in lung adenocarcinoma. J. Cancer 16, 1167\u20131180 (2025).","journal-title":"J. Cancer"},{"key":"2848_CR43","doi-asserted-by":"crossref","unstructured":"Manjarrez-Ordu\u00f1o, N. et al. Circulating T cell subpopulations correlate with immune responses at the tumor site and clinical response to PD1 inhibition in non-small cell lung cancer. Front. Immunol. 9, 1613 (2018).","DOI":"10.3389\/fimmu.2018.01613"},{"key":"2848_CR44","doi-asserted-by":"publisher","first-page":"100725","DOI":"10.1016\/j.omto.2023.09.001","volume":"31","author":"R Chen","year":"2023","unstructured":"Chen, R. et al. miR-146a inhibits ovarian tumor growth in vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T cell infiltration. Mol. Ther. Oncolytics 31, 100725\u2013100725 (2023).","journal-title":"Mol. Ther. Oncolytics"},{"key":"2848_CR45","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.4049\/jimmunol.1800906","volume":"201","author":"S Sarkar","year":"2018","unstructured":"Sarkar, S. et al. Programming of CD8 T cell quantity and polyfunctionality by direct IL-1 signals. J. Immunol. 201, 3641\u20133650 (2018).","journal-title":"J. Immunol."},{"key":"2848_CR46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molimm.2017.03.018","volume":"87","author":"M Li","year":"2017","unstructured":"Li, M., Yu, D., Ni, B. & Hao, F. Interleukin-1 receptor associated kinase 1 is a potential therapeutic target of anti-inflammatory therapy for systemic lupus erythematosus. Mol. Immunol. 87, 94\u2013101 (2017).","journal-title":"Mol. Immunol."},{"key":"2848_CR47","first-page":"624","volume":"37","author":"Y Li","year":"2022","unstructured":"Li, Y., Li, W., Lin, J., Lv, C. & Qiao, G. miR-146a enhances the sensitivity of breast cancer cells to paclitaxel by downregulating IRAK1. Cancer Biother. Radiopharm. 37, 624\u2013635 (2022).","journal-title":"Cancer Biother. Radiopharm."},{"key":"2848_CR48","doi-asserted-by":"crossref","unstructured":"Jain, A., Kaczanowska, S. & Davila, E. IL-1 receptor-associated kinase signaling and its role in inflammation, cancer progression, and therapy resistance. Front. Immunol. 5, 533 (2014).","DOI":"10.3389\/fimmu.2014.00553"},{"key":"2848_CR49","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/nm.4405","volume":"23","author":"JY Goh","year":"2017","unstructured":"Goh, J. Y. et al. Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. Nat. Med. 23, 1319\u20131330 (2017).","journal-title":"Nat. Med."},{"key":"2848_CR50","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.2147\/OTT.S185662","volume":"12","author":"M Yang","year":"2019","unstructured":"Yang, M., Qin, X., Qin, G. & Zheng, X. The role of IRAK1 in breast cancer patients treated with neoadjuvant chemotherapy. Onco Targets Ther. 12, 2171\u20132180 (2019).","journal-title":"Onco Targets Ther."},{"key":"2848_CR51","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/jha2.591","volume":"3","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju, N. et al. Risk-adjusted safety analysis of the oral JAK2\/IRAK1 inhibitor pacritinib in patients with myelofibrosis. EJHaem 3, 1346\u20131351 (2022).","journal-title":"EJHaem"},{"key":"2848_CR52","doi-asserted-by":"publisher","first-page":"33416","DOI":"10.18632\/oncotarget.26058","volume":"9","author":"JW Singer","year":"2018","unstructured":"Singer, J. W. et al. Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget 9, 33416\u201333439 (2018).","journal-title":"Oncotarget"},{"key":"2848_CR53","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","volume":"14","author":"IC Salaroglio","year":"2019","unstructured":"Salaroglio, I. C. et al. Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma. J. Thorac. Oncol. 14, 1458\u20131471 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"2848_CR54","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.4049\/jimmunol.1002514","volume":"187","author":"B Castella","year":"2011","unstructured":"Castella, B. et al. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between V\u03b39V\u03b42 T cells, \u03b1\u03b2 CD8+ T cells, regulatory T cells, and dendritic cells. J. Immunol. 187, 1578\u20131590 (2011).","journal-title":"J. Immunol."},{"key":"2848_CR55","doi-asserted-by":"crossref","unstructured":"Alessandr\u00ec, L. et al. rCASC: reproducible classification analysis of single-cell sequencing data. GigaScience 8, giz105 (2019).","DOI":"10.1093\/gigascience\/giz105"},{"key":"2848_CR56","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/s41467-023-37353-8","volume":"14","author":"I Nofech-Mozes","year":"2023","unstructured":"Nofech-Mozes, I., Soave, D., Awadalla, P. & Abelson, S. Pan-cancer classification of single cells in the tumour microenvironment. Nat. Commun. 14, 1615\u20131615 (2023).","journal-title":"Nat. Commun."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02848-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02848-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02848-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:01:54Z","timestamp":1789426914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02848-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2848"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02848-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SN: Advisor\/Speaker Bureau: AZ, AMG, Beigene, Accord, MSD, Roche, Takeda, Sanofi, J&J, Pfizer, Lilly, Thermo Fisher, Novartis, Pierre Fabre. PB: Institutional research grant: Pfizer, Roche; Consultancy\/Advisory Board: AstraZeneca, MSD, GenMab, Novartis, Beigene, Diaceutics. AM: Institutional research grant: PharmaMar; Consultancy\/Advisory Board: Beigene, Sanofi, PharmaMar, GSK. CR: Institutional research grant: PharmaMar.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"382"}}